Using a modified Delphi methodology to gain consensus on the use of dressings in chronic wounds management by Russell, D et al.
Page 1 of 12 
 
Abstract: 
Background:  Managing chronic wounds is associated with a 
burden to patients, caregivers, health services and society. 
The cost of treating these conditions is increasing and there is 
a lack of clarity regarding the role of dressings in improving 
outcomes. With chronic wounds becoming more prevalent, 
and the cost of wound management increasing, strategies 
using dressings to minimise the healthcare burden are 
essential.   
Methods: A systematic review of the literature was carried out 
on the role of dressings in DFU, and VLU management 
strategies, their effectiveness, associated resource use/cost, 
and quality of life burden for patients. From this evidence base 
statements were written, regarding chronicity in wounds, 
burden of illness, healing time, and the role of matrix 
metalloproteinases (MMPs), early interventions and 
dressings. A modified Delphi methodology involving two 
iterations of email questionnaires followed by a face to face 
meeting was used to validate the statements, in order to 
arrive at a consensus for each. Clinical experts were selected; 
representing nurses, surgeons, podiatrists, academics, and 
policy experts.  
Results: In the first round, 38/47 statements reached or 
exceeded the consensus threshold of 80% and none were 
rejected. According to the protocol, any statement not 
confirmed or rejected had to be modified using the comments 
from participants and resubmitted. In the second round, 5/9 
remaining statements were confirmed and none rejected, 
leaving 4 to discuss at the meeting. All final statements were 
confirmed with at least 80% consensus. 
Conclusions: This modified Delphi panel sought to gain clarity 
from clinical experts surrounding the use of dressings in the 
management of chronic wounds. A full consensus statement 
was developed to help clinicians and policy makers improve 
the management of patients with these conditions. 
 
Background 
 
Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs) are 
two of the most common lower limb wounds.1 A growing 
global epidemic of chronic wounds not only leaves patients in 
pain and with a reduced quality of life, but also causes a 
significant financial burden to healthcare providers 
worldwide.2,3 In 2016, independent research funded by the 
National Health Service’s (NHS) National Institute of Health 
Research (NIHR) stated that the prevalence of long lasting 
ulcers below the knee that take longer than six weeks to heal 
is seen in 15 out of every 10,000 people,4 which is an increase 
of threefold on a previous estimate. The impact of these 
wounds, including DFU and VLU is likely to continue to rise, 
with an aging population and increasing incidence of 
diabetes5 accelerating the growth.  
 
The burden of these wounds is felt not only by patients, but 
also by carers, families, employers, and by the healthcare 
system. Should a DFU remain unhealed and eventually 
require amputation, this is devastating for the patient and 
their subsequent decreased level of independence, will place 
a strain on the family or carers. The financial burden to the 
healthcare system is substantial; an estimate of the cost of 
chronic wounds to the NHS is between £2.3-3.1 billion (for 
the year 2005/6).6 Diabetes UK estimated that in 2014-15 
around £1 billion (or approximately £1 in every £140 the NHS 
spends) is spent on foot ulcers or amputations each year.7 
Prescribing costs are also rising, in 2004 £122 million was 
spent on wound dressings, and 8 years later in 2012, the 
prescribing costs for wound dressings had risen by 51% to 
£184 million.8 The rise in spending on chronic wounds can be 
partially attributed to the increasing numbers of people 
presenting with DFU and VLU. The increased demand has led 
to a need to create an efficient treatment pathway that will 
both improve the welfare of substantial numbers of patients 
and also reduce overall NHS spending. The Scottish 
Intercollegiate Guidelines Network (SIGN) guideline on the 
management of Venous Leg Ulcer states that “Simple non-
adherent dressings are recommended in the management of 
venous leg ulcers”.9. However, this guidance was issued in 
2010, and the more recent  National Institute for Health and 
Care Excellence (NICE) guidelines on the treatment of DFU, 
updated in January 2016, asks the research question: What is 
the clinical effectiveness of different dressing types in treating 
diabetic foot problems?10 
To help improve outcomes, it is important to understand the 
expected healing process of a wound and being able to 
identify exactly when a wound deviates from this could 
reduce costs. Recently, there has been an increase in the 
understanding of wound physiology and how the micro-
environment of a wound is important to achieving wound 
healing. It has been found that a key family of enzymes, 
MMPs, have a fundamental role in wound healing. As a result 
of this understanding, there are new treatment options that 
work to change the wound environment to promote and 
stimulate healing. 
 
The uncertainty regarding the use of dressings in wound 
management and their place in the treatment pathway is 
clear; many recent Cochrane reviews have not been able to 
recommend a single type of dressing.11 To address this, it was 
proposed to convene a panel of clinical experts to produce a 
consensus statement using a modified Delphi methodology. 
This is an anonymous, iterative process, where a group of 
multidisciplinary experts aimed to reach agreement in areas 
where there is a lack of explicit and clear guidance for clinical 
practice.12 In addition to the role of MMPs, this study aimed 
to provide understanding on a range of topics including; the 
definition of chronicity in wounds, the burden of illness, 
clinical outcomes of reducing healing time and the impact of 
early interventions on clinical and economic outcomes. 
 
Methods  
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A systematic literature review (SLR) was the first part of this 
study. A search strategy consistent with the  PICO framework, 
focusing on Population, Intervention, Comparison and 
Outcomes, was formulated for the area of wound 
management. A full list of search terms is available in Table 1. 
 
 
Table 1: Search terms used 
Search terms Item 
(Wound* AND Chronic) OR (Ulcer 
AND (Pressure OR Diabetic Foot OR 
Venous Leg)))   
Population 
Management OR Treatment OR Care Intervention 
Dressing* Intervention 
Resource AND (Use OR Utilisation) 
OR Cost 
Outcome 
Quality of Life OR Patient Outcomes 
OR Burden OR Impact 
Outcome 
Effectiveness OR Efficacy Outcome 
 
Online databases were then searched using these search 
terms for publications looking at clinical, economic and 
quality of life outcomes in patients with chronic wounds such 
as DFU, VLU and PU. 
 
Table 2: List of databases used 
 
 
Of the 3417 articles retrieved, 827 were included at initial 
screening. The rest were duplicate of deemed irrelevant at 
this early stage.  After this, a pre-defined set of inclusion and 
exclusion criteria were applied to the search results. These 
criteria are shown in Table 3. These criteria were applied by 
2 reviewers from the Manchester Met project team.  
 
A broad range of study types was included to allow a large 
evidence base for the statements that were to be 
generated.  
 
Eventually, 145 full texts were used in order to inform the 
development of the statements. A schematic of the literature 
search is shown in Figure 1.  
 
Table 3: Inclusion and Exclusion Criteria 
 
 
Search tool Count 
Science Direct 2479 
NICE Evidence search 805 
Medline (PubMed) 78 
CRD (University of York) 47 
Cochrane 8 
Total exported to EndNote:  3417 
Inclusion criteria 
Population Diabetic Foot Ulcer, Venous Leg Ulcer, or a study 
of mixed wounds that included the 
aforementioned.  
Interventions Dressings 
Outcomes Wound healing, Wound Area Reduction, healing 
rate, Quality of Life Outcomes, Economic 
outcomes 
Study design o Randomised Controlled Trials 
o Patient Reported Outcomes 
o Observational studies 
o Epidemiology Studies 
o Modelling 
o Case Studies 
o Economic studies 
o Database Studies 
o Systematic/ Literature Reviews 
o Treatment pathway/guidelines 
Language 
restrictions 
English Language 
Search dates After 1987 
Exclusion criteria 
Population Paediatrics (<18), Acute wounds (including 
Burns, Trauma, Surgery) 
Interventions Surgical 
Novel non-surgical (including electrical 
stimulation, hyperbaric treatment, electrical 
stimulation) 
Infection control measures (including silver, 
iodine or honey) 
Debridement (including, surgical, maggot) 
Bioengineered skin substitutes 
Offloading 
Outcomes Not meeting inclusion criteria  
Study design In vitro studies, review or discussion articles 
Language 
restrictions 
Non-English language (if the abstract was 
available in English and enough data was 
available, this was included in the data 
extraction, otherwise these articles were 
excluded).  
Search dates Before 1987 
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Figure 1: PRISMA Search strategy flow diagram 
 
In order to develop the statements that would be taken 
forward to the Delphi panel for review, a thematic analysis of 
the papers was undertaken. 145 texts were reviewed by the 
project lead, and 304 direct quotations from 131 of the were 
extracted in four set categories; epidemiology, clinical 
effectiveness, quality of life, and economics and cost. These 
quotations were reviewed and agreed as representative by 
the Manchester Met project team.  
 
A lack of clarity presented itself in many ways, including; an 
inconclusive systematic literature review, a dressing being 
deemed as not having enough robust evidence, or as 
opposing results being published on the same subject.  
 
An assessment of the quotations highlighted many sub 
categories, which were aggregated under the themes shown 
in Table 4, and used to develop the 47 statements to put 
forward to the Delphi panel for voting and further 
refinement.  
 
Table 4: Themes 
Theme Number of statements 
Definition of chronicity 3 
Burden of illness 10 
Reduce healing time 4 
The role of matrix 
metalloproteinases 
13 
Early interventions lead to 
better outcomes 
7 
The use of dressings and 
treatments 
10 
 
In order to validate the statements, and assess the evidence 
using a group of experts and their combined wealth of clinical 
and academic expertise, a modified Delphi methodology was 
carried out. The Delphi method was developed by the RAND 
Corporation in the 1950’s, and aims to arrive at an expert 
consensus using an iterative process. The method consists of 
a group of experts anonymously replying to a questionnaire; 
then receiving the group feedback, after which this process 
repeats itself.   
 
The modified process that was used for this study included 
two rounds of anonymous email voting followed by a face-to-
face meeting. The meeting was face to face with all 
participants and was a very structured round-table meeting 
with strict agenda.  The threshold for consensus was set at 
80%, and participants had the option of voting yes or no 
against the statements, thereby confirming or rejecting the 
statements respectively. Using previous Delphi methodology 
studies as a guide, 80% consensus was a relatively high 
threshold.  
 
The participants were sent an excel sheet workbook that 
consisted of 6 sheets: 
1. Cover sheet: For participants to record their name, 
affiliation and job title.  
2. Introduction: An overview of the workbook and the 
process.  
3. Instructions: An overview of the tasks needed to be 
completed by the participant. 
4. Voting sheet: For the participants to record their 
responses.  
5. References: Full listing of quotations, with 
bibliographic information and classification of 
evidence using a modified SIGN system.  
6. Search methodology: An overview of the search 
strategy and results of the SLR.  
 
The voting sheet allowed participants to click on hyperlinks to 
review the evidence base for each statement; each study was 
also given a level of evidence classification using a modified 
version of the SIGN Evidence classification shown in table 5. 
Participants were invited to review the evidence base for the 
statements, and were given the full bibliographic information 
and evidence classification for each source used.  
 
Table 5: Modified SIGN Evidence Classification: 
Level Description 
1 
Guidelines, Meta-analyses, systematic reviews of 
RCTs, or RCTs  
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2 
Economic Evaluations, Systematic reviews of case 
control or cohort studies. Case control or cohort 
studies 
3 
Non-analytic studies, e.g. case reports, case 
series, in vivo or in vitro studies 
4 Expert opinion 
 
 
The panel of 12 members were identified and approached for 
their experience treating and managing wounds such as DFU, 
VLU and PU. A range of different specialities were included 
on the panel; this is to reflect the multidisciplinary care 
pathway for patients with these chronic wounds. The final 
clinical experts included in the panel are listed in Table 6.  
 
Any statement that fell in between 80% ‘yes’ and 80% ‘no’ 
was amended by the Manchester Met project team using the 
comments made by the participants and resubmitted to them 
in the following round.  
 
This modified methodology was chosen for its iterative and 
impartial rigour that allowed each participant a fair chance to 
voice their opinions in the anonymous voting rounds, a step 
that is important in empowering panel members to voice 
their opinions amongst the multidisciplinary group.  
 
This study was reviewed and approved by Manchester 
Metropolitan University Faculty Academic Ethics Committee, 
with number 1486. Panel members gave informed consent to 
participate both verbally and in writing. 
 
 
Results  
 
Twelve panel members were approached, however one 
panel member dropped out of the process and another was 
unable to complete the workbook in time for their comments 
to be included, yet joined the discussion and endorsed the 
consensus. A final ten participants completed the first 
workbook and the results of the first anonymous round of 
voting were as follows: 38 statements confirmed, 9 
statements did not reach the 80% consensus threshold and 0 
statements were rejected. 18 statements were agreed by 
100% of the panel.  
 
The same 10 participants completed the second workbook 
which consisted of the 9 statements that had been amended 
and resubmitted, 5 statements were agreed, and 4 did not 
reach the 80% consensus threshold, 0 were rejected. 
 
At the meeting, the remaining 4 statements were amended 
and presented to the panel, where they gained consensus. 
Due to the large number of statements confirmed before the 
final round; it was considered prudent to revisit comments on 
statements which had been confirmed with a level of 80-99%, 
in order to increase the level of agreement and ensure 
semantic clarity.  
 
After the meeting, the statements were collected, ordered, 
and presented in the below consensus statement for 
dissemination. The statements themselves are identified with 
bold text, and underlined words or phrases are defined in 
Table 5 at the end of the statement.  
 
 
Consensus statement 
 
There is a need for consensus when the literature or guidance 
does not provide clarity. This lack of clarity can be identified 
by: contradictory information in the literature, a lack of 
robust evidence or systematic reviews that prove 
inconclusive. Recent reports and guidelines on wound 
management are not specific and do not make 
recommendations on treatment options. The Cochrane 
Review “Protease-modulating matrix treatments for healing 
venous leg ulcers” identifies the need for further research 
into these dressings.13 
 
Contents of this consensus statement:  
1. The role of matrix metalloproteinases (MMPs) 
2. Quality of life for patients with DFU, VLU and PU 
3. Time to healing and NHS burden 
4. Early intervention and economic impact 
5. Conclusions 
6. Definitions 
7. Panel Members 
 
1. The role of MMPs in chronic wounds: 
Wounds are deemed chronic when they do not follow a 
normal healing pattern and can be perpetuated by having an 
underlying aetiology.14-19 A normal healing pattern contains 
four phases of healing categorised according to the activity of 
their cellular components: haemostasis phase, inflammatory 
phase, proliferative phase, and maturation (or remodelling) 
phase. Wounds with underlying aetiologies include Diabetic 
Foot Ulcers (DFUs), Venous Leg Ulcers, (VLUs) and Pressure 
Ulcers (PUs). 
Matrix metalloproteinases (MMPs) are a part of healthy 
healing, expressed at the inflammatory phase of early wound 
healing. 20 - 24  MMPs are enzymes that are responsible for 
degradation of the extracellular matrix and also play a pivotal 
role in regulation of cell proliferation, migration, 
differentiation, and death. When a wound moves to the 
proliferative phase of healing, the level of MMPs fall.25 If the 
wound does not advance to the proliferative phase of healing 
in an expected time period, it can be considered chronic. 
These chronic wounds have been shown to have up to 30 
times the level of MMPs than an acute wound.26-31 
Wounds such as DFU, VLU and PU are shown to have raised 
levels of MMPs from first presentation to a wound care 
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specialist.32-36 With raised levels of MMPs, the wound is stuck 
in the inflammation phase, leading to the destruction of new 
tissues,37-40 thus preventing progression to the next stage of 
healing.41-43 
Persistently elevated levels of MMP are predictive of non-
healing44-48 and specifically, of the 24 known MMPs, MMP-9 
has been shown to be detrimental to healing, killing growth 
factors. 49 - 53  Interventions that modulate the wound 
environment may enhance healing 54 - 60  because evidence 
suggests removing excess MMPs from wounds improves 
healing. 61-65  A specific MMP-9 inhibitor is potentially more 
effective in stimulating healing66-68 than standard care alone. 
In addition to modulating the wound environment, the ideal 
dressing should be cost-effective, acceptable to the patient 
and also be effective on older and larger wounds.69-84 
The lipido-colloid nano-oligosaccharide factor (TLC-NOSF) 
technology inhibits MMPs and accelerates healing,85-88 it has 
been shown as superior to basic foam dressings in reducing 
healing time 89 , 90  and as superior to oxidized regenerated 
cellulose and collagen, especially in non-responsive, older 
wounds. 91  Further to this, TLC- NOSF has been shown to 
reduce levels of MMP-9 in vitro.92, 93 
 
2. Quality of life for patients with DFU, VLU and PU 
Wounds such as DFU, VLU and PU are associated with 
increased morbidity and mortality.94 - 99   In addition to this 
increased risk of death and high likelihood of comorbidities, 
patients with these conditions suffer significantly reduced 
health related quality of life across dimensions such as pain, 
physical limitation, social isolation, and anxiety/depression.100-
104 The psychological impact of these wounds can be severe, 
with patients reporting a loss of self, poor self-image, feelings 
of being a burden and hopelessness for the future.105-109 These 
wounds can take a long time to heal and have a high likelihood 
of recurrence, which again detracts from quality of life.110-116 
Clinician focus tends to be on the treatment of the wound, 
which fails to account for the large psychological and social 
burden experienced by some patients.117-120 
The pain caused by chronic wounds impacts quality of life.121-
124  Dressing changes can be a cause of pain: products and 
techniques to minimise this are recommended.125-129 Dressing 
changes and local management of the wound site is 
considered easy in most cases with the TLC-NOSF dressing,130, 
131  which has also been shown to significantly reduce 
pain/discomfort and anxiety/depression for a patient.132, 133 
In addition to the health related quality of life burden, the 
patient also faces financial costs such as time away from work, 
early retirement, medications, dressings, and transport 
costs.134-137 Chronic wounds are a burden to both the patient 
and to the carer 138  and this cost is often excluded or 
underestimated in cost-effectiveness models.139-144 
 
3. Time to healing and NHS burden 
As well as a quality of life burden to patients, DFU, VLU and 
PU are a significant workload burden for healthcare 
providers.145-155 Home visits are a key driver of the cost to treat 
chronic wounds. 156 - 160  Advanced dressings require fewer 
changes and therefore fewer visits are more likely to reduce 
costs, especially when the dressing also reduces healing 
time.161-165 Protease inhibitors have been shown to be a cost-
effective option. 166 - 169  Management plans associated with 
shorter treatment periods and fewer adverse events are more 
cost-effective.170-175 Ulcers can be slow to heal, with wound 
size and duration affecting healing.176 - 180  The initial wound 
area reduction at 4 weeks is predictive of healing by 24 
weeks.181-183 
 
4. Early intervention and economic impact 
Early diagnosis and treatment of a DFU, VLU or PU can improve 
quality of life for a patient. 184 , 185  This early investment in 
treatment provides a reduction in long-term costs; prolonged 
futile treatment is more costly.186-189 There is a need for a long-
term view from decision makers, for example, the purchase 
price of a dressing is not indicative of cost-effectiveness.190  
Some ulcers are more expensive to manage, these include: 
chronic wounds, recurrent wounds, and older wounds.191-195 
Older wounds are harder and more expensive to heal so early 
intervention will reduce the healing time and cost.196-200 VLU is 
more prevalent in older populations who may benefit from 
less invasive treatment options.201-204 An adjunctive therapy 
such as a dressing that modulates the microenvironment can 
promote faster healing in complicated wounds. 205 - 211  An 
adjunctive therapy to standard wound care should be 
considered in cases where you anticipate wound healing may 
be compromised.212-217 
5. Conclusions 
This consensus process seeks to provide clarity for the 
management of chronic wounds. We have agreed that: 
 Chronic wounds including DFU, VLU and PU significantly 
impair a patient’s health and quality of life and this needs 
to be taken into consideration in patient care with the 
aim of reducing healing time. 
 Inhibiting MMPs plays an important role in wound 
healing and raised levels of these enzymes have been 
shown to be present in DFU, VLU and PU.  
 Early interventions are a more cost-effective option, 
both in terms of health and quality of life improvement 
for a patient and in financial savings to the healthcare 
system 
 
 
6. Definitions 
 
Table 5: Consensus statement definitions 
Term  
(in order of appearance) 
Definition 
Normal healing pattern A normal healing pattern 
contains four phases of 
healing categorised 
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according to the activity of 
their cellular components. 
The phases are haemostasis 
phase, inflammatory phase, 
proliferative phase, and 
maturation (or remodelling) 
phase. Normal healing will 
move through these phases 
naturally at a predictable 
rate.  
Aetiology The cause or origin of a 
disease or disorder as 
determined by medical 
diagnosis. (The American 
Heritage® Medical 
Dictionary Copyright © 
2007, 2004 by Houghton 
Mifflin Company) 
Matrix metalloproteinases 
(MMPs) 
By regulating the integrity 
and composition of the 
extracellular matrix, these 
enzymes play a pivotal role 
in the control of signals 
elicited by matrix molecules 
that regulate cell 
proliferation, 
differentiation, and death. 
(Farlex Partner Medical 
Dictionary © Farlex 2012) 
Acute wound An acute wound is an injury 
to the skin that occurs 
suddenly rather than over 
time. It heals at a 
predictable and expected 
rate according to the 
normal wound healing 
process: ( 
http://www.woundcarecen
ters.org/article/wound-
types/acute-wounds) 
Basic foam dressings A foam dressing with no 
active agents. 
Morbidity  A diseased condition or 
state. 
Mortality Likelihood of death, or 
death rate. 
Significantly Having reached statistical 
significance. 
Carer An unpaid carer; a relative, 
friend or neighbour. 
Healthcare Providers Any individual, institution, 
or agency that provides 
health services. 
Advanced dressings Dressings that regulate 
wound healing by simple 
physicochemical means, 
typically by controlling 
moisture levels. (NICE 
Evidence summary 
[ESMPB2] March 2016) 
Adjunctive therapy Another treatment used 
together with the 
primary treatment. Its 
purpose is to assist the 
primary treatment. 
(PubMed Health Glossary: 
Source: NIH - National 
Cancer Institute) 
Standard wound care Standard care used to 
promote wound healing, 
which can be achieved 
through off-loading in DFU, 
compression in VLU and/ or 
repositioning in PU 
7. Panel Members: 
 
The panel was made up of a multidisciplinary group and was 
supported by a group of technical experts to advise on the 
methodology.  The panel members with voting rights are 
listed in Table 7, and the technical experts in Table 6. 
  
Table 6: Technical experts 
 
 
Table 7: Clinical experts  
Name Title Place of work 
Professor 
Nancy Devlin 
Panel Chair Person Office of Health 
Economics 
April Betts Project Manager Manchester 
Metropolitan 
University 
Professor 
Isaac Odeyemi 
Visiting Professor of 
Health Technology 
Assessment and 
Health Policy 
Manchester 
Metropolitan 
University 
Professor 
Francis Fatoye 
Professor of Health 
Economics and 
Outcomes 
Manchester 
Metropolitan 
University 
Dr Gillian 
Yeowell 
MSc Advanced 
Physiotherapy 
programme leader 
Manchester 
Metropolitan 
University 
Richard 
Shorney 
Meeting Facilitator Real Healthcare 
Solutions 
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Discussion 
 
A lack of clear evidence supporting a single treatment 
strategy, or mandated clinical guidance can have a 
detrimental impact on emerging technologies. Reviews 
relying solely on the literature, and not clinical opinion, often 
present uncertainty, such as the review carried out by 
Cochrane in 2016, Protease-modulating matrix treatments 
for healing venous leg ulcers. This systematic literature review 
declared the evidence not conclusive and the certainty 
judged as low. This however, does not mean that the 
available evidence is of no use to clinicians, as demonstrated 
by the consensus panel. New studies, published and ongoing, 
have been designed to assess the efficacy and tolerability of 
specific protease modulating matrix treatments. 
 
New evidence available has shown promising results. A 
manuscript exploring the real world usage of a protease 
modulating dressing has now been published (Munter 2017). 
The quality of life endpoints associated with this dressing 
have been explored in Meaume 2017, and ClinicalTrials.gov 
shows that a trial titled “Assessment of the Efficacy and 
Safety of a New Wound Dressing in the Local Treatment of 
Diabetic Foot Ulcers” is due to report. The Cochrane 
Collaboration has also just registered a protocol looking into 
the efficacy of using protease levels to predict healing 
outcomes in VLU patients. 
 
The objective of this project was to provide clear guidance for 
clinical practice on a range of topics where there is a lack of 
clarity in the literature. The rigorous process that was 
followed has generated a consensus statement, agreed by a 
multidisciplinary panel. 
 
The certainty of evidence for wound care dressings is low, as 
evidenced by a series of inconclusive Cochrane reviews 
(hydrocolloid, alginate, hydrogel, foam, protease-modulating 
matrix treatments) that found low levels of evidence and high 
risk of bias. 218,219, 220, 221, 222. Cochrane risk of bias tools judge 
using blinding criteria that are difficult to meet in any wound 
trial; due to practical issues with packaging, nurse 
involvement etc. In light of this; this consensus panel allowed 
the participants to judge the validity of the evidence in the 
context of their own clinical expertise.  
 
The consensus statement agrees that chronic wounds have a 
significant impact on a patient, regarding both their health 
and quality of life. In order to mitigate this for the patient and 
the healthcare provider, early intervention is key to 
successful treatment. The role of MMPs in wound healing is 
important, and in wounds with raised MMP levels, such as 
DFU, VLU and PU, a MMP inhibitor can expedite wound 
healing.  
 
The modified Delphi process has many benefits, such as the 
anonymity enjoyed by the participants in the first two rounds. 
This helped to ensure a wide range of expert opinions were 
collected with the return of the workbooks. The face to face 
meeting after this was to allow the panel to come together as 
a group and review the study output. It is possible that the 
face-to-face element may weaken the strength of the 
methodology, however an individual’s earlier comments 
remained anonymous and the Chairperson present ensured 
that the review of comments was without derision. The 
process is also iterative, and the systematic review of the 
literature carried out prior to the Delphi process ensured it is 
supported by evidence, repeatable and transparent. 
 
The strength of the process became apparent after the first 
round, with 80% of the statements reaching the consensus 
threshold. This could be attributed to a number of factors, 
Name Title Place of work 
Dr Leanne Atkin 
Vascular Nurse 
Specialist 
Mid Yorks NHS 
Dr Caroline 
Dowsett 
Nurse Consultant 
Tissue Viability 
East London 
NHS Foundation 
Trust, London 
Sarah Gardner 
Clinical Lead,  
Tissue Viability 
Oxford Health 
NHS Foundation 
Trust 
Dr Julie Green 
Senior Lecturer in 
Nursing, Director of 
Postgraduate 
Programmes 
Keele University, 
School of 
Nursing and 
Midwifery 
Dr Chris Manu 
Consultant 
Diabetologist and 
Clinical Researcher 
in Diabetic Foot 
Kings College 
Hospital, 
London 
Tracey 
McKenzie 
Head of Tissue 
Viability Services 
Torbay and  
Southern Devon 
NHS Foundation 
Trust 
Helena Meally Hospital Podiatrist 
Leeds Teaching 
Hospitals NHS 
Trust 
Louise Mitchell 
Clinical Lead 
Podiatrist 
Birmingham 
Community 
HealthCare 
Julie Mullings 
Lead Tissue Viability 
Nurse 
University 
Hospital South 
Manchester 
David Russell 
Consultant Vascular 
Surgeon and 
Honorary Clinical 
Associate Professor 
Leeds Teaching 
Hospitals NHS 
Trust 
Andrew Sharpe 
Advanced Podiatrist 
and Lecturer 
Practitioner 
West Lancashire 
Community 
Service, Virgin 
Care Ltd and 
University of 
Huddersfield 
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including the body of evidence presented in the workbook, 
the anonymity provided preventing individuals unduly 
influencing others, or perhaps the lack of clarity in the 
literature is not reflected in clinical practice. At the end of the 
process, all of the original statements had been confirmed, 
with modifications. This can once again be attributed to the 
fact that the methodology allowed the participants’ 
comments to inform amendment of the statements when 
resubmitted. This flexibility in the approach allowed for more 
participation and elicited more expertise from the panel 
members. However, a limitation of the methodology relates 
to the binary yes/no structure of the questions. This process 
could be further improved by amending the voting to a scale 
which would allow for more ranking of the statements.  
 
The Delphi process differs from a traditional expert panel or 
advisory board, the participants of an advisory board are 
likely to meet once, for a few hours and have a semi-
structured discussion, often based on some pre-work The 
modified Delphi methodology used in this study allowed 
direct access to the evidence base for the statements, and 
1 Guest J., Ayoub N., McIlwraith T., et al. Health economic burden that wounds impose 
on the National Health Service in the UK. BMJ Open. 2015; 5: 12. Article: E009283. 
2 Posnett J., Gottrup F., Lundgren H., Saal G.. The resource impact of 
wounds on healthcare providers in Europe. Journal of Wound Care.  
2009; 18:4, 154-161. 
3 Fife C., Carter, M. Walker, D., Thomson, B. Wound Care Outcomes and Associated 
Cost Among Patients Treated in US Outpatient Wound Centers: Data From the US 
Wound Registry. Wounds. 2012; 24:1, 10–17. 
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